Table 2.
Effects of SP and PAA.
| SP baseline | After 16 weeks | PAA baseline | After 16 weeks | |
|---|---|---|---|---|
| IPSS | ||||
| Total | 13.4 ± 5.5 | 9.6 ± 5.3 | 14.5 ± 6.2 | 10.4 ± 5.6 |
| Storage | 6.2 ± 2.5 | 4.4 ± 2.6 | 8.1 ± 2.9 | 4.4 ± 2.6 |
| Voiding | 7.3 ± 4.3 | 5.2 ± 4.1 | 8.4 ± 4.3 | 5.2 ± 4.1 |
| QOL | 4.0 ± 1.1 | 2.9 ± 1.3 | 4.0 ± 0.9 | 2.9 ± 1.3 |
| OABSS | 4.9 ± 2.5 | 3.9 ± 2.9 | 6.8 ± 3.3 | 3.9 ± 2.9 |
| IIEF5 | 1.2 ± 0.5 | 1.4 ± 0.5 | 1.4 ± 0.5 | 2.3 ± 1.4 |
| ICIQ-SF | 1.9 ± 3.2 | 1.6 ± 2.7 | 5.3 ± 4.9 | 2.9 ± 3.8 |
| UFM | ||||
| RV (ml) | 30.8 ± 22.3 | 41.9 ± 43.2 | 36.4 ± 21.5 | 41.9 ± 43.2 |
| Qmax (ml/s) | 13.3 ± 6.8 | 12.3 ± 5.3 | 12.6 ± 6.7 | 12.3 ± 5.3 |
| 8-OHdG (ng/mlCRE) | 18.4 ± 8.2 | 22.5 ± 20.8 | 17.4 ± 5.4 | 18.9 ± 5.4 |
Notes: IPSS, International prostate symptom score; QOL, quality of life; OABSS, Overactive Bladder Symptom Score; IIEF5, 5-item version of the International Index of Erectile Function; ICIQ-SF, Consultation on Incontinence Questionnaire e-short Form; UFM, uroflowmetry; RV, residual urine volume; Qmax, maximum flow rate; 8OHdG, 8-hydroxy-2′-deoxyguanosine.